Inside Products and Services - March 2015

March 2015, Vol 3, No 3 - Inside Products and Services

New Drugs/Devices

The following are some of the recent approvals announced by the US Food and Drug Administration (FDA):

  • Zarxio (filgrastim-sndz) is the first biosimilar product approved in the United States. The drug is biosimilar to Amgen Inc’s Neupogen (filgrastim), and is approved for the same indications, including patients with severe neutropenia.
  • Cresemba (isavuconazonium sulfate), a new intravenous antifungal product, was approved for adult patients with invasive aspergillosis and invasive mucormycosis. The drug belongs to a class of drugs called azole antifungal agents, which target the cell membrane of a fungus.
  • Avycaz (ceftazidime-avibactam) is a new intravenous antibacterial drug product approved to treat adult patients with complicated abdominal infections, in combination with metronidazole, and patients with complicated urinary tract infections, including pyelonephritis, who have limited or no alternative treatment options.
  • ResQCPR System, a system of 2 devices for first responders to use while performing cardiopulmonary resuscitation (CPR) on patients who are experiencing cardiac arrest, was approved. The device may improve the patient’s chances of surviving cardiac arrest.

New Generic

The following is a recent first-time generic drug approval by the FDA:

  • The first generic version of Fu­silev (levoleucovorin calcium; Spectrum Pharmaceuticals, Inc) for injection has been approved by the FDA. The generic drug name is levoleucovorin calcium injection, 10 mg/mL, and is manufactured by Sandoz, Inc.

New Rulings, Announcements

The following are some recent FDA rulings and announcements:

  • US v Specialty Compounding LLC, et al. US District Judge Lee Yeakel entered a consent decree of permanent injunction between the United States and Specialty Compounding LLC, of Cedar Park, TX, and co-owners. Specialty Compounding manufactured purportedly sterile injectable drug products that tested positive for bacterial contamination. The consent decree prohibits the company and its owners from manufacturing, holding, or distributing sterile drugs until they comply with the Federal Food, Drug, and Cosmetic Act and its regulations, in addition to other requirements.



Sources

  1. US Food and Drug Administration. New and generic drug approvals. www.fda.gov/Drugs/NewsEvents/ucm130961.htm. Updated March 17, 2015. Accessed March 18, 2015
  2. US Food and Drug Administration. Press an­nouncements. www.fda.gov/NewsEvents/News room/PressAnnouncements/default.htm. Updated March 17, 2015. Accessed March 18, 2015.
Related Items
Inside Products and Services - October 2015
October 2015, Vol 3, No 10 published on October 21, 2015 in Inside Products and Services
Inside Products and Services - September 2015
September 2015, Vol 3, No 9 published on September 23, 2015 in Inside Products and Services
Inside Products and Services - August 2015
August 2015, Vol 3, No 8 published on August 17, 2015 in Inside Products and Services
Inside Products and Services - July 2015
July 2015, Vol 3, No 7 published on July 23, 2015 in Inside Products and Services
Inside Products and Services - June 2015
June 2015, Vol 3, No 6 published on June 23, 2015 in Inside Products and Services
Inside Products and Services - May 2015
May 2015, Vol 3, No 5 published on May 19, 2015 in Inside Products and Services
Inside Products and Services - April 2015
April 2015, Vol 3, No 4 published on May 4, 2015 in Inside Products and Services
Inside Products and Services - February 2015
February 2015, Vol 3, No 2 published on March 10, 2015 in Inside Products and Services
Last modified: May 27, 2015
  • American Health & Drug Benefits
  • The Journal of Hematology Oncology Pharmacy
  • Lynx CME
  • The Oncology Pharmacist

Search